Page 34 - Boxed Warning News Today

/PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living...

RAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of clinical data from its broad and advancing cardiovascular pipeline and portfolio at the upcoming American College of Cardiology’s 72nd Annual Scientific Session toget...

The FDA has approved Lamzede (velmanase alfa-tycv) for the treatment of non-CNS manifestations of alpha-mannosidosis in adult and pediatric patients.

Elucirem and Vueway (gadopiclenol) are now available for use to detect and visualize lesions with abnormal vascularity in the CNS and the body.

The FDA has approved Cibinqo (abrocitinib) to include patients 12 to <18 years of age with refractory, moderate to severe atopic dermatitis.

Jesduvroq (daprodustat) is approved to treat anemia due to CKD in adults who have been receiving dialysis for at least 4 months.

Jesduvroq (daprodustat) is approved to treat anemia due to CKD in adults who have been receiving dialysis for at least 4 months.

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI®...

The FDA has approved Tecartus (brexucabtagene autoleucel) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

27.01.2023 - Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that CARTITUDE-4, the Phase 3 study ...